Antiinfective biotechs face partnering gap

Article Abstract:

Biotech companies entering the antiinfective sector face an added difficulty in finding development and marketing partners due to a shift in the pharmaceutical groups' focus on antiinfectives. However, Vicuron, formed with the merger of US firm Versicor and Italian pharma spin-out Bio-Search Italia, has demonstrated that anti-infection companies could build a decent-market capitalization by combining robust late stage assets with an ability to implement their business plan.

Management dynamics, Alliances, partnerships, Management, Company business management, Alliances and partnerships, Vicuron Pharmaceuticals Inc.

---

A taste of the future

Article Abstract:

Senomyx has signed a clutch of licensing deals with large corporations to commercialize molecules generated through the discovery programme. Senomyx applies the high-throughput screening methods developed for drug discovery, to hunt for novel molecules that modulate the activity of taste receptors.

Contracts & orders received, Contracts & orders let, Contracts, Discovery and exploration, Contract agreement, Molecules, Senomyx Inc.

---

Similar abstracts:

• Abstracts: The art of persuasion. And so to the future. Twists and u-turns
• Abstracts: Imperfect information: The persistence of price dispersion on the web. The negative effect of policy restrictions on consumers' post-purchase reactions to price-matching guarantees
• Abstracts: Deconstructing Myogen's market cap. Niche indications could drive higher valuations. Are small biotechs still underselling themselves?

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.